ENTITY
BeiGene

BeiGene (BGNE US)

140
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bullishHuazhu Group
10 Sep 2020 13:41

Huazhu HK Secondary Listing - Needs the Money but Looks Toppish

Huazhu Group (HTHT US) has filed confidentially for a US$1bn secondary listing in Hong Kong, as per media reports. In our earlier insight, China...

Logo
411 Views
Share
31 Aug 2020 11:31

Yum China HK Listing - Relatively Bigger, Should Offer a Bigger Discount

Yum China Holdings, Inc (YUMC US) aims to raise around US$2.5bn in its Hong Kong secondary listing.  I had taken an early look at the deal in...

Logo
383 Views
Share
16 Aug 2020 17:17

HSCI Index Rebalance - Stock Connect Flows Coming Up

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
488 Views
Share
bullishHuazhu Group
12 Aug 2020 14:36

Huazhu HK Secondary Listing - Early Look - Needs the Cash More than Most Secondary Candidates

Huazhu Group (HTHT US) has filed confidentially for a US$1bn secondary listing in Hong Kong, as per media reports. In our earlier insight, China...

Logo
500 Views
Share
bullishS&P 500 INDEX
22 Jul 2020 21:34

U.S. Equity Strategy: Bullish Outlook Intact

With the S&P 500 breaking above the June highs and the Russell 2000 bullishly inflecting topside a ~1-month base, it signals a continuation of...

Logo
392 Views
Share
x